Kyverna Therapeutics, Inc. (KYTX)

Kyverna Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	104.66	34.65	37.74	76.07
Short-Term Investments	216.92	22.9	13.59	-
Cash & Short-Term Investments	321.59	57.54	51.32	76.07
Cash Growth	526.61%	12.12%	-32.53%	-
Prepaid Expenses	3.79	3.12	1.93	1.02
Total Current Assets	325.37	60.66	53.25	77.09
Property, Plant & Equipment	11.38	10.61	12.44	7.81
Other Long-Term Assets	2.44	3.92	1.23	0.59
Total Assets	339.2	75.2	66.92	85.49
Accounts Payable	9.93	4.36	1.45	0.77
Accrued Expenses	17.12	9.06	7.66	7.77
Current Portion of Leases	3.93	2.92	2.28	0.81
Current Unearned Revenue	-	-	-	6
Other Current Liabilities	-	3.52	0.57	0.58
Total Current Liabilities	30.99	19.86	11.95	15.93
Long-Term Leases	5.21	6.16	8.29	4.74
Long-Term Unearned Revenue	-	-	-	1.03
Other Long-Term Liabilities	0.3	-	0.01	1.33
Total Liabilities	36.49	26.02	20.25	23.02
Additional Paid-In Capital	528.59	4.64	1.71	0.53
Retained Earnings	-226.03	-136.04	-75.68	-46.78
Comprehensive Income & Other	0.15	0	-0.03	-
Total Common Equity	302.71	-131.4	-74	-46.25
Shareholders' Equity	302.71	49.18	46.68	62.47
Total Liabilities & Equity	339.2	75.2	66.92	85.49
Total Debt	9.14	9.08	10.56	5.56
Net Cash (Debt)	312.45	48.46	40.76	70.51
Net Cash Growth	666.60%	18.91%	-42.20%	-
Net Cash Per Share	11.27	71.95	89.48	265.19
Filing Date Shares Outstanding	43.17	43.12	0.55	0.27
Total Common Shares Outstanding	43.17	1.25	0.55	0.27
Working Capital	294.39	40.81	41.3	61.16
Book Value Per Share	7.01	-105.11	-133.91	-173.96
Tangible Book Value	302.71	-131.4	-74	-46.25
Tangible Book Value Per Share	7.01	-105.11	-133.91	-173.96
Machinery	5.58	4.17	3.74	3.35
Leasehold Improvements	0.92	0.65	0.46	0.08

Source: S&P Capital IQ. Standard template. Financial Sources.